Retigabine Dihydrochloride — CAS 90274-24-1

Retigabine Dihydrochloride is a high-purity Active Pharmaceutical Ingredient (API) classified as an Anticonvulsant and Potassium Channel Opener. Mediocon Inc manufactures GMP-compliant Retigabine Dihydrochloride at its state-of-the-art facility in Aurangabad, Maharashtra, India, supplying pharmaceutical companies worldwide.

• Treatment of partial-onset seizures in epilepsy
• KCNQ2–5 potassium channel opener mechanism
• Adjunctive therapy in adult epilepsy patients
• Research use in neurological disorders

• GMP Certified manufacturing facility in Aurangabad, Maharashtra, India
• Full pharmacopoeial compliance: IP / BP / EP / USP standards
• Complete documentation: Certificate of Analysis (CoA), MSDS, Certificate of Origin
• Stringent in-process quality control at every manufacturing stage
• HPLC purity testing and spectroscopic identification (IR, NMR)
• Cold-chain and controlled-environment storage facilities available
• Exported to 40+ countries with full regulatory support